Dr. Abdelilah Arredouani joined QBRI in March 2012 as a Scientist in the Diabetes Research Center. He holds a PhD in Biomedical Sciences from the Faculty of Medicine at University of Louvain-La-Neuve in Belgium. Prior to joining QBRI he worked in Netherlands at the Department of Neurosciences in Erasmus Medical Center in Rotterdam, in United Kingdom at the Department of Pharmacology in Oxford University, and in Qatar at the Department of Physiology and Biophysics in Weill Cornell Medicine. During his PhD, he studied the contribution of the calcium stores in the endoplasmic reticulum to glucose-induced calcium response and insulin secretion from the pancreatic beta cell in the context of type 2 diabetes.

Dr. Arredouani was a key player in the discovery of the NAADP receptor, the two pore channels, and Ned-19, a specific antagonist of the NAADP. Since joining QBRI in 2012, Dr. Arredouani has been involved in projects related to the identification of biomarkers to predict type 2 diabetes using systems biology approaches. He has published in high impact peer-reviewed journals including Nature, Nature Chemical Biology, Current Biology, Diabetes and JBC.